19May

Epic Research Weekly Fundamental Report Of Dlf On 16 May 2015

COMPANY INFORMATION

DLF’s primary business is development of residential, com- mercial and retail properties. The Company has significant exposure across businesses, segments and geographies. From developing 22 major colonies in Delhi, DLF is now pre- sent across 15 states-24 cities in India. DLF has also forayed into infrastructure, SEZ and hotel businesses.

Latest News about the company:

In a fresh order Thursday against DLF, the Competition Com- mission of India (CCI) ruled that realty giant DLF was guilty of indulging in “unfair and abusive” business practices in sale of apartments in a Gurgaon housing project. CCI has asked DLF Gurgaon Home Developers Private Limited and its group companies to “cease and desist” from such unfair trade practices, but did not impose any fresh mone- tary penalty as Rs 630 crore fine has already been slapped on DLF for similar violation during the same period in a sepa- rate case. Subsequently, the complainants approached CCI alleging abuse of dominant position by the company and the fair trade regulator ordered a probe by its investigative arm.

DLF results on 20 may 2015

DLF Ltd has informed BSE that a meeting of the Board of Di- rectors of the Company will be held on May 20, 2015, inter alia, to consider and approve:
1. Audited Financial Results along with Q4 results for the year/quarter ended March 31, 2015
2. Recommendation of Dividend, if any, for the FY 2014-15.

Technical observation

DLF recently broke down below medium term support of around Rs 145 and we have seen a pennant getting formed on the daily chart which is indicating that this continuation of downtrend is what we are expecting. So the recommendation is to sell DLF for a target of Rs 105 with a stop loss at Rs 140

DLF FUTURE is looking weak on charts, short build up has been seen, we may see more downside, if it sustains below 130 levels. We advise selling around 125-130 levels with strict stop loss 140 for the targets of 115-105 levels.

Get the full report from our website – http://www.epicresearch.co/report-request/submit-request/weekly-reports/fundamental

11May

Epic Research Private Limited – Weekly Fundamental Report HUL 9 May 2015

COMPANY INFORMATION

Incorporated in the year 1933, Hindustan Unilever Limited is a FMCG company. HUL has a diversified presence in the FMCG sector with more than 35 brands spanning 20 distinct categories including soaps and detergents, shampoos, skin care, toothpastes, and packaged foods. British-Dutch company Unilever PLC and its Affiliates are the promoters of HUL and own 52.5 % shares in the Company (On 30 April 2013, Unilever PLC announced plans to increase its stake in the Company to 75 % by way of an open offer). Over the years, HUL has grown substantially by acquiring landmark brands and has managed to maintain its dominant market position in various categories. HUL’s portfolio includes leading household brands including Lux, Lifebuoy, Surf Excel, Rin, Wheel, Fair & Lovely, Pond’s, Vaseline, and Lakme.

HUL volume growth rises 6%, Q4 net profit at Rs.1018 Crore: HUL has posted a net profit of Rs. 10180.80 mn for the quarter ended March 31, 2015 as compared to Rs. 8721.30 million for the quarter ended March 31, 2014. Total Income has increased from Rs. 72447.30 mn for the quarter ended March 31, 2014 to Rs. 77740.40 million for the quarter ended March 31, 2015. The Company has posted a net profit of Rs. 43152.60 mn for the year ended March 31, 2015 as compared to Rs. 38674.90 million for the year ended March 31, 2014. Total Income has increased from Rs. 286401.60 mn for the year ended March 31, 2014 to Rs. 314240.10 million for the year ended March 31, 2015.During the quarter, the Domestic Consumer business grew at 9%, with 6% underlying volume growth, both ahead of market.

Financial Year 2014-15: Competitive and profitable growth delivered: The Domestic Consumer business grew by 10% with 5% underlying volume growth, both ahead of market. Profit before interest and tax (PBIT) grew by 17% with PBIT margin improving +90 bps. Profit after tax but before exceptional items, PAT (bei), grew by 8% to Rs. 3843
Crores, impacted by the higher tax rate. Net Profit at Rs. 4315 Crores was up 12%, aided by the exceptional income arising from property related sales. The strong track record of cash generation was sustained as cash from operations exceeded Rs.5000 Crores for yet another year.

HINDUSTAN UNILEVER FUTURE is looking strong on charts, long build up has been seen, we may see more upside, if it sustains above 900 levels. We advise buying around 880-900 levels with strict stop loss 850 for the targets of 925-950 levels.

 

Get the full report from our website – http://www.epicresearch.co/report-request/submit-request/weekly-reports/fundamental

10May

Kindly Note

Dear Traders / Investors,

Please follow below mentioned strategies for better trades:

1) Do trade in all calls.

2) Trade with equal lots/amount in all calls.

3) Trade according to the given levels only.

4) Always trade with Stop Loss only.

5) Trade in those calls which you get through SMS or Link only.

Kindly note that investment is subjected to market risk and Epic do not guarantee any kind of assured return and thus we do not have any refund policy. Please do trade in all our calls provided through SMS or web link only. Epic Research do not commit or assure any guaranteed returns, if so found in any of our communication please inform us.

For further assistance please mark a mail on:

[email protected]

Or

Phone: 0731-2580606 / 0731-2580627 /0731-2580739

7May

Weekly Fundamental Report Of Divi’s Laboratories Limited

Divi’s Laboratories Limited develops new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. Divis Laboratories was set up in the year 1990 and established its first manufacturing facility in the year 1995 in Hyderabad and a second manufacturing facility at Visakhapatnam in the year 2002.

The Hyderabad plant comprises of 13 multi-purpose production blocks While the Visakhapatnam site has 14 multi-purpose production blocks. The Company’s product portfolio comprises of two broad segments i) Generic APIs (Active Pharma Ingredients) and Nutraceuticals and ii) Custom Synthesis of APIs, intermediates and specialty ingredients for innovator pharma giants.

The Company operates predominantly in export markets and has a broad product portfolio under generics and custom synthesis. Exports constituted around 90% of gross sales in FY 2013 are as against 89% in the previous year. Exports to advanced markets comprising Europe and America accounted for 77% of business.

Outlook and Valuation :

Divi’s Labs (DIVI) 3QFY15 PAT at INR2.2b was 8% below expectations, mainly on slower topline growth. Revenues grew 6% YoY to INR7.9b (6% miss), while EBITDA margin (36% vs 38% est) was impacted by weaker business mix, resulting in higher miss at EBITDA level (INR2.8b, down 1% YoY). Forex gain of INR112m cushioned profitability, adjusted for which net profit declined 5% YoY at NR2.1b.

We have cut our FY15-17E forecasts by 3-4% mainly to factor lower EBITDA margins (37% now, 100bp lower) on a weaker business mix as well as onset of new capex addition phase. DIVI trades at 22x FY16E and 18x FY17E (P/E), largely in line with its historic average, limiting valuation upside. Onset of large capex addition would also restrainscope for earnings surprise. Strong Balance sheet (net cash), high return ratios (RoE at ~27%) provide valuationcushion. We downgrade our rating to Neutral (from Buy earlier), with our revised target price of 1650-1550.

DIVIS LAB FUTURE is looking weak on charts, short build up has been seen, we may see more downside, if it sustains below 1800 levels. We advise selling around 1750-1800 levels with strict stop loss 1900 for the targets of 1650-1550 levels.

Get the full report from our website – http://www.epicresearch.co/report-request/submit-request/weekly-reports/fundamental

© 2008-17. All Rights Reserved. Epic Research Pvt. Ltd.